# Ticagrelor

## Brilinta 90mg

| TAH Drug Code      | [OBRI](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=OBRI)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|:-------------------|:--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | 1. Acute coronary syndrome (ACS) or history of myocardial infarction (MI) When used in combination with aspirin， BRILINTA reduces the incidence of thrombotic cardiovascular (CV) events in patients with acute coronary syndrome (ACS) or those with a history of myocardial infarction (MI) who are at high risk of arterial thrombotic events. 2. Acute ischemic stroke or transient ischemic attack (TIA) When used in combination with aspirin， BRILINTA is indicated for reducing the risk of stroke in patients with acute ischemic stroke (NIHSS score ? 5) or high-risk transient ischemic attack (TIA). |
| Dosing             | Acute coronary heart disease: loading dose as 180mg and followed by 90mg BID for 12 months. Patient with MI history combined with high risk of arterial thrombosis， needed an extended treatment: 60mg BID. 對於曾接受經皮冠狀動脈介入治療(PCI)且出血風險增加的ACS病人，可考慮在3個月後停用Aspirin，在此情況，Brilinta作為單一抗血小板治療應持續9個月。                                                                                                                                                                                                                                                            |
| Hepatic Impairment | Dose adjustment required                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Contraindications  | 1. History of intracranial hemorrhage 2. Active bleeding 3. Contraindicated in patients with known hypersensitivity to ticagrelor or any component of this product (e.g.， angioedema) 4. Severe hepatic impairment                                                                                                                                                                                                                                                                                                                                                                                                 |
| Adverse Effects    | Dyspnoea， epistaxis， GI haemorrhage， subcutaneous or dermal bleeding， bruising， procedural site haemorrhage.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Pregnancy          | No (Limited) Human Data – Animal Data Suggest Risk                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Lactation          | No (Limited) Human Data - Potential Toxicity                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| More Info          | [UpToDate](https://www.uptodate.com/contents/ticagrelor-drug-information)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |

